Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 26;7(2):e830.
doi: 10.1097/HS9.0000000000000830. eCollection 2023 Feb.

Aptamers Targeting Von Willebrand Factor: What and Why?

Affiliations
Editorial

Aptamers Targeting Von Willebrand Factor: What and Why?

Roger E G Schutgens. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The aptamer BT200 in relation to von Willebrand factor. (A) Secondary structure of BT200. (B) Cocrystal structure of the unpegylated aptamer BT100 with the von Willebrand factor A1 domain (from Zhu et al).

References

    1. Zhu G, Chen X. Aptamer-based targeted therapy. Adv Drug Deliv Rev. 2018;134:65–78. - PMC - PubMed
    1. Arshavsky-Graham S, Heuer C, Jiang X, et al. . Aptasensors versus immunosensors—Which will prevail? Eng Life Sci. 2022;22:319–333. - PMC - PubMed
    1. Zhu S, Gilbert JC, Hatala P, et al. . The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer. J Thromb Haemost. 2020;18:1113–1123. - PMC - PubMed
    1. Mayr FB, Knöbl P, Jilma B, et al. . The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion (Paris). 2010;50:1079–1087. - PubMed
    1. Cataland SR, Peyvandi F, Mannucci PM, et al. . Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012;87:430–432. - PubMed

Publication types